Member Info for BuenaVista

I believe we keep and can trade our AIM shares as now. But what happens with the share price? Can it change after close of trading on AIM due to trading on NASDAQ until 21:30 UK time? I suppose so.

I think the R&D Spotlight Science Day on London will be shortly after the presentations at the EORTC conference in Barcelona, 23-25 October, certainly not before. We may get a date for it on Monday.

I'm good thanks CTSFO, hope you are too. I get live prices elsewhere and without ads or pop-ups or anything - HL. Wasn't aware you can get live prices here - do you still get ads? The half mile of scrolling on my phone is something else though and the peering through ads and having to close the cookies pop-up and pop-up whinge about adblocker.

And then there's the line spacing for every line feed that makes formatting lists for clarity impossible. I'd join any half decent competitor BB in a flash.

...has anyone ever come across another website where you have to scroll down half a mile to get to the content? And then peer through useless promotional content that no one wants to watch?

A competitor to LSE would be laughing all the way to the bank.

Good point well made Timmy. It's going to be windy 🌬️...

I admire the effort but it's still a crap poem.

Drugs are given approval for DEFINED DOSING REGIMENS for SPECIFIED INDICATIONS (which, for cancer, means cancer types/subtypes). Neither of these have been decided, let alone tested yet. As regards Accelerated Approval, see https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval

This is an Israeli version of the WO patent filed in June 2019

From the IL311536 patent:

Application number: IL20240311536 20240317

Priority number(s): US201862680300P 20180604 ; WO2019US35374 20190604

From the WO2019236567A2:

Worldwide applications: 2019 IL SG KR IL AU JP CA EP TW CN US WO

It's quite an old patent. Here are the details.

https://patents.google.com/patent/WO2019236567A2/en?assignee=avacta&oq=avacta

It covers PDCs, AffDCs, and ADCs and all other DCs, e.g. Affibodies, Affilins, Anticalins, Atrimers, Avimer, DARPins, FN3 scaffolds, etc, etc, etc.

@PJT12,

How many more years of your Pharmacology degree course do you still have to do?

So basically they overpaid for some vile anal excrement.

@Ceesor, do you think that's why Paul Cuddon wrote that there were no complete responses and the results didn't meet expectations?

It was RorkesDrift

Gallmat, you need to complete that pharmacology degree (what year are you in?) before you can truly evaluate the value of Avacta's platform against what the competition offers.

Oh well done all you green boxes! Argue amongst yourselves, children.

I'M IGNORING EGGY'S DELIBERATE ATTEMPT TO DERAIL THE THREAD - I SUGGEST YOU ALL DO THE SAME.

Paul Cuddon's wife is Lorna Cuddon, Managing Director of Zyme Communications Ltd.

https://www.zymecommunications.com/lorna-cuddon/

Zyme was Avacta's Investor and Media Relations advisor until sometime between 28 Jun 2023 ( https://www.lse.co.uk/rns/AVCT/result-of-annual-general-meeting-50zfh2b5whxtm48.html ) and 21 Jul 2023 ( https://www.lse.co.uk/rns/AVCT/issue-of-equity-and-total-voting-rights-aeo6ys88mnxz40o.html ), by which time Avacta had changed to Consilium Strategic Communications.

Do we know when and why that change was made? It would seem a very petty thing for the Cuddon's to start a vendetta about, unless there was bad blood.

I've reported Paul Cuddon to Deutsche Bank's 'ethics' dept for misconduct. Let's see if the response is any more helpful than the one Diplomat51 got.

Super bantz PL

Anyone wishing to report Cuddon's hatchet job as misguided, manipulative, malicious or, given that he bears a grudge against Avacta on behalf of his wife, vindictive can email report.misconduct@db.com

For me the key point is that - whilst Cuddon never states what the 'expectations' are that, according to him, are not being met - the trial is very much meeting all safety and tolerability expectations, as well as showing markedly reduced side-effects. Early indications of efficacy are clearly there, which is amazing for proof of concept in a heavily pre-treated metastasised end-of-life population of patients, many with cancers known to not be treatable with doxorubicin, in a Phase 1a (dose escalation) study.

Thanks. So no complete translation and no link to what was on Twitter.